Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

We recently published a list of These 10 Stocks Just Rocked The Market. In this article, we are going to take a look at where ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that its experimental drug, when combined with Novo Nordisk ...

In the latest quarter, 21 analysts provided ratings for Regeneron Pharmaceuticals (NASDAQ:REGN), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview ...

Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 43 unusual trades. Delving into the details, we found 16% of traders were bullish, while 53% showed bearish ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life ...

Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...